Rosmantuzumab
Modify Date: 2024-04-05 18:06:23
Rosmantuzumab structure
|
Common Name | Rosmantuzumab | ||
|---|---|---|---|---|
| CAS Number | 1684393-04-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RosmantuzumabRosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. |
| Name | Rosmantuzumab |
|---|
| Description | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Rosmantuzumab (25 mg/kg；腹腔注射，每周一次，持续 4 周) 显著保护动物免于发生肝纤维化[1]。 Rosmantuzumab (25mg /kg；腹腔注射，每两周一次，持续 6 周) 在博莱霉素诱导的肺纤维化小鼠模型中，显著抑制皮肤厚度、胶原沉积和 α-SMA 阳性细胞数量[1]。 Animal Model: Male C57B1/6J CCl4 liver fibrosis mouse models[1] Dosage: 25 mg/kg Administration: Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks Result: Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation. |
| References |
| No Any Chemical & Physical Properties |